LQ0.F Dextech Medical AB

Healthcare Biotechnology Frankfurt Exchange
0.9000 EUR
Close of Nov 12, 2026
0.6000 1.12
Market cap
EUR 16.6M
P/E
-
P/B
10.84x
ROE
-34.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.

Is LQ0.F undervalued?

Graham number

The Graham number of Dextech Medical AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Dextech Medical AB fundamental analysis

No fundamental analysis for Dextech Medical AB yet.

Dextech Medical AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Dextech Medical AB

DexTech Medical AB (publ) engages in the development of drug candidates with application in urological oncology, primarily prostate cancer in Sweden. The company's lead candidate, OsteoDex, which has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is…

Full company profile